Ameet Sarpatwari

3.4k total citations · 1 hit paper
129 papers, 2.1k citations indexed

About

Ameet Sarpatwari is a scholar working on Economics and Econometrics, Pediatrics, Perinatology and Child Health and Pharmacology. According to data from OpenAlex, Ameet Sarpatwari has authored 129 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 87 papers in Economics and Econometrics, 38 papers in Pediatrics, Perinatology and Child Health and 30 papers in Pharmacology. Recurrent topics in Ameet Sarpatwari's work include Pharmaceutical Economics and Policy (68 papers), Health Systems, Economic Evaluations, Quality of Life (53 papers) and Pharmaceutical studies and practices (34 papers). Ameet Sarpatwari is often cited by papers focused on Pharmaceutical Economics and Policy (68 papers), Health Systems, Economic Evaluations, Quality of Life (53 papers) and Pharmaceutical studies and practices (34 papers). Ameet Sarpatwari collaborates with scholars based in United States, United Kingdom and Canada. Ameet Sarpatwari's co-authors include Aaron S. Kesselheim, Jerry Avorn, Drew Provan, Adrian C. Newland, Jonathan J. Darrow, Dimitri Bennett, James B. Bussel, Roberto Stasi, Nichola Cooper and Jodi B Segal and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Ameet Sarpatwari

120 papers receiving 2.0k citations

Hit Papers

The High Cost of Prescription Drugs in the United States 2016 2026 2019 2022 2016 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The High Cost of Prescription Drugs in the United States
    2016 394 citations Aaron S. Kesselheim, Jerry Avorn et al. JAMA profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ameet Sarpatwari United States 22 1.1k 376 357 351 246 129 2.1k
Bishal Gyawali Canada 32 1.6k 1.5× 225 0.6× 221 0.6× 279 0.8× 158 0.6× 221 4.3k
Charles L. Bennett United States 21 300 0.3× 1.8k 4.8× 214 0.6× 223 0.6× 207 0.8× 54 3.4k
Arrigo Schieppati Italy 34 364 0.3× 358 1.0× 275 0.8× 356 1.0× 45 0.2× 75 4.2k
George Dranitsaris Canada 28 449 0.4× 160 0.4× 169 0.5× 183 0.5× 37 0.2× 105 2.3k
Margaret Piper United States 20 231 0.2× 798 2.1× 138 0.4× 95 0.3× 130 0.5× 52 2.9k
Carolien H. Smorenburg Netherlands 27 238 0.2× 74 0.2× 264 0.7× 221 0.6× 153 0.6× 99 3.0k
Adriana Ceci Italy 25 278 0.3× 370 1.0× 709 2.0× 104 0.3× 38 0.2× 101 2.1k
Melissa A. Robb United States 10 555 0.5× 42 0.1× 147 0.4× 119 0.3× 102 0.4× 12 2.2k
Ted Wun United States 28 317 0.3× 684 1.8× 184 0.5× 138 0.4× 22 0.1× 75 2.9k
James D. Chambers United States 22 671 0.6× 62 0.2× 148 0.4× 109 0.3× 85 0.3× 90 1.2k

Countries citing papers authored by Ameet Sarpatwari

Since Specialization
Citations

This map shows the geographic impact of Ameet Sarpatwari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ameet Sarpatwari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ameet Sarpatwari more than expected).

Fields of papers citing papers by Ameet Sarpatwari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ameet Sarpatwari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ameet Sarpatwari. The network helps show where Ameet Sarpatwari may publish in the future.

Co-authorship network of co-authors of Ameet Sarpatwari

This figure shows the co-authorship network connecting the top 25 collaborators of Ameet Sarpatwari. A scholar is included among the top collaborators of Ameet Sarpatwari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ameet Sarpatwari. Ameet Sarpatwari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sarpatwari, Ameet, Zhigang Lu, Massimiliano Russo, et al.. (2025). Physician Experiences With and Perspectives on Clozapine Prescribing. JAMA Network Open. 8(2). e2459311–e2459311.
2.
Egilman, Alexander C., et al.. (2024). Federal Trade Commission Actions on Prescription Drugs, 2000-2022. JAMA. 331(23). 2029–2029. 2 indexed citations
3.
Wang, Junyi, et al.. (2024). Commercial markups on pediatric oncology drugs at 340B pediatric hospitals. Pediatric Blood & Cancer. 71(9). e31158–e31158. 1 indexed citations
4.
Tu, S. Sean, et al.. (2024). Patent Portfolios Protecting 10 Top-Selling Prescription Drugs. JAMA Internal Medicine. 184(7). 810–810. 5 indexed citations
5.
Feldman, William B., Mufaddal Mahesri, Ameet Sarpatwari, et al.. (2024). Removing the FDA’s Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan. JAMA Network Open. 7(7). e2419873–e2419873.
6.
Morrow, Richard L., Barbara Mintzes, Patrick C. Souverein, et al.. (2022). Influence of drug safety advisories on drug utilisation: an international interrupted time series and meta-analysis. BMJ Quality & Safety. 31(3). 179–190. 3 indexed citations
7.
Sarpatwari, Ameet, et al.. (2022). Patient and Caregiver Experiences With and Perceptions of Risk Evaluation and Mitigation Strategy Programs With Elements to Assure Safe Use. JAMA Network Open. 5(1). e2144386–e2144386. 9 indexed citations
8.
Sarpatwari, Ameet, Apurvakumar Pandya, Emily P. Hyle, & Govind Persad. (2021). COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?. Annals of Internal Medicine. 175(2). 280–282. 2 indexed citations
9.
Bhasale, Alice L, et al.. (2021). Regulatory authority and clinical acceptability: Physicians' responses to regulatory drug safety warnings. British Journal of Clinical Pharmacology. 88(2). 713–722. 7 indexed citations
10.
Bhasale, Alice L, Ameet Sarpatwari, Marie L. De Bruin, et al.. (2020). Postmarket Safety Communication for Protection of Public Health: A Comparison of Regulatory Policy in Australia, Canada, the European Union, and the United States. Clinical Pharmacology & Therapeutics. 109(6). 1424–1442. 15 indexed citations
11.
Kesselheim, Aaron S., et al.. (2020). Transformative Models to Promote Prescription Drug Innovation and Access: A Landscape Analysis. eYLS (Yale Law School). 19(2). 2. 1 indexed citations
12.
Sarpatwari, Ameet, et al.. (2020). Changes in Erythropoiesis Stimulating Agent Use Under a Risk Evaluation and Mitigation Strategy (REMS) Program. Drug Safety. 44(3). 327–335. 5 indexed citations
13.
Desai, Rishi, Ameet Sarpatwari, Sara Z. Dejene, et al.. (2019). Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims. PLoS Medicine. 16(3). e1002763–e1002763. 49 indexed citations
14.
Sarpatwari, Ameet & Aaron S. Kesselheim. (2019). Reforming the Orphan Drug Act for the 21st Century. New England Journal of Medicine. 381(2). 106–108. 30 indexed citations
15.
Desai, Rishi, Chandrasekar Gopalakrishnan, Sara Z. Dejene, et al.. (2019). Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients. Clinical Pharmacology & Therapeutics. 107(6). 1334–1342. 6 indexed citations
16.
Lynch, Holly Fernandez, Patricia J. Zettler, & Ameet Sarpatwari. (2018). Promoting Patient Interests in Implementing the Federal Right to Try Act. JAMA. 320(9). 869–869. 19 indexed citations
17.
Curfman, Gregory, Leo Beletsky, & Ameet Sarpatwari. (2017). Benefits, Limitations, and Value of Abuse-Deterrent Opioids. JAMA Internal Medicine. 178(1). 131–131. 8 indexed citations
18.
Hwang, Thomas J., Aaron S. Kesselheim, & Ameet Sarpatwari. (2017). Value-Based Pricing and State Reform of Prescription Drug Costs. JAMA. 318(7). 609–609. 22 indexed citations
19.
Kesselheim, Aaron S., Jerry Avorn, & Ameet Sarpatwari. (2016). The High Cost of Prescription Drugs in the United States. JAMA. 316(8). 858–858. 394 indexed citations breakdown →
20.
Sarpatwari, Ameet, Christopher T. Robertson, David Yokum, & Keith A. Joiner. (2014). Crowdsourcing Public Health Experiments: A Response to Jonathan Darrow's Crowdsourcing Clinical Trials. SSRN Electronic Journal. 98(6). 2326–2345.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Bishal Gyawali Breakdown of academic impact, for papers by Charles L. Bennett Breakdown of academic impact, for papers by Arrigo Schieppati Breakdown of academic impact, for papers by George Dranitsaris Breakdown of academic impact, for papers by Margaret Piper Breakdown of academic impact, for papers by Carolien H. Smorenburg Breakdown of academic impact, for papers by Adriana Ceci Breakdown of academic impact, for papers by Melissa A. Robb Breakdown of academic impact, for papers by Ted Wun Breakdown of academic impact, for papers by James D. Chambers
Rankless by CCL
2026